{"id":"torsemide-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Ototoxicity (at high doses)"},{"rate":null,"effect":"Dehydration"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL1148","moleculeType":"Small molecule","molecularWeight":"348.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Torsemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This leads to increased urine output and reduced blood volume and pressure. It is commonly used in cardiovascular conditions characterized by fluid overload, such as edema and hypertension.","oneSentence":"Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:53.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with renal disease"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06995144","phase":"PHASE4","title":"Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-05-28","conditions":"Heart Failure, Edema, Pulmonary Congestion","enrollment":20},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07201584","phase":"PHASE1","title":"A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:","status":"RECRUITING","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2025-09-05","conditions":"Healthy Adult Male and Female Volunteers","enrollment":26},{"nctId":"NCT06670534","phase":"PHASE2","title":"A Dose-finding Study of JMKX003142 in Treatment of Renal Edema","status":"RECRUITING","sponsor":"Jemincare","startDate":"2025-01-07","conditions":"Edema Secondary, Edema Leg","enrollment":216},{"nctId":"NCT06708611","phase":"PHASE4","title":"A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-01-15","conditions":"Heart Failure","enrollment":5},{"nctId":"NCT06176794","phase":"PHASE2","title":"Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2024-11-15","conditions":"Heart Failure","enrollment":1},{"nctId":"NCT03354897","phase":"PHASE4","title":"Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-04-05","conditions":"Cardiovascular Diseases, Hypertension","enrollment":228},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122},{"nctId":"NCT04921566","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2021-06-05","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT01558674","phase":"PHASE1","title":"A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Renal Impairment, Heart Failure","enrollment":11},{"nctId":"NCT03214874","phase":"PHASE1","title":"Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2017-06-19","conditions":"Congestive Heart Failure, Chronic Kidney Diseases","enrollment":24},{"nctId":"NCT03215875","phase":"PHASE1","title":"A Food Effect Study of 60mg ER Torsemide","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2017-10-17","conditions":"Food-drug Interaction","enrollment":28},{"nctId":"NCT00602303","phase":"NA","title":"Bioequivalency Study of Torsemide Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2003-09","conditions":"Edema","enrollment":28},{"nctId":"NCT00602615","phase":"NA","title":"Bioequivalency Study of Torsemide Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2003-09","conditions":"Edema","enrollment":28},{"nctId":"NCT02087332","phase":"PHASE4","title":"Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.","status":"UNKNOWN","sponsor":"Society of Specialists in Heart Failure","startDate":"2014-04","conditions":"Arterial Hypertension, Chronic Heart Failure","enrollment":78},{"nctId":"NCT00953303","phase":"PHASE2, PHASE3","title":"The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Hebei Medical University","startDate":"2009-01","conditions":"Heart Failure","enrollment":102},{"nctId":"NCT00653549","phase":"PHASE1","title":"Bioavailability Study of Torsemide Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-04","conditions":"To Determine Bioequivalence Under Fasting Conditions","enrollment":26},{"nctId":"NCT00654043","phase":"PHASE1","title":"Bioavailability Study of Torsemide Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-04","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"ANAPHYLACTIC SHOCK"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CORONARY ARTERY DISEASE"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"DRUG EFFECT DECREASED"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ER Torsemide tablets"],"phase":"marketed","status":"active","brandName":"Torsemide Tablets","genericName":"Torsemide Tablets","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with renal disease, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}